Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,450.99 +69.64 (+0.83%) Bitcoin USD
62,960.75 +1,856.04 (+3.04%) CMC Crypto 200
1,305.82 -52.19 (-3.84%)
NeuroSense Therapeutics Ltd. (NRSN)
After hours:
| Previous close | 1.2300 |
| Open | 1.2100 |
| Bid | 1.1100 x 100 |
| Ask | 1.2100 x 100 |
| Day's range | 1.0800 - 1.2500 |
| 52-week range | 0.4000 - 2.3300 |
| Volume | |
| Avg. volume | 293,970 |
| Market cap | 20.347M |
| Beta (5Y monthly) | 1.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8300 |
| Earnings date | 25 May 2024 - 29 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.25 |
PR NewswireNeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces new analyses from its Phase 2b PARADIGM clinical trial, demonstrated a statistically significant slowing of disease progression in high-risk ALS patients treated with PrimeC by 43% (p=0.02) as compared to placebo in the pre-specified per protocol (PP) population analysis after 6 months of treatment. The slowing of disease progression demonstrated by P
- PR Newswire
NeuroSense Announces First Quarter 2024 Business Update
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.
PR NewswireNeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer's Disease (AD) drug development with Genetika+, a leader in precision medicine for psychiatry and neurology. The multi-phase collaboration, which will commence in NeuroSense's currently ongoing Phase 2 AD clinical trial, leverages Genetika+'s state-of-the-art technology that derives frontal cortex neurons from individ
